FcRn affinity-pharmacokinetic relationship of five human IgG4 antibodies engineered for improved in vitro FcRn binding properties in cynomolgus monkeys

Drug Metabolism and Disposition

Volumn 40, Issue 8, 2012, Pages 1545-1555

  Datta Mannan, Amita ^a   Chow, Chi Kin ^a   Dickinson, Craig ^b   Driver, David ^b   Lu, Jirong ^a   Witcher, Derrick R ^a   Wroblewski, Victor J ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Applied Molecular Evolution   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G4; MONOCLONAL ANTIBODY;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CORRELATION ANALYSIS; HAPLORHINI; IN VITRO STUDY; MALE; NONHUMAN; PH; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ANIMALS; CELL LINE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOGLOBULIN G; MACACA FASCICULARIS; PROTEIN BINDING; RECEPTORS, FC;

MACACA FASCICULARIS;

EID: 84863912958     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.045864     Document Type: Article

References (28)

1. Chaparro-Riggers J, Liang H, Devay RM, Bai L, Sutton JE, Chen W, Geng T, Lindquist K, Galindo Casas M, Boustany LM, et al. (2012) Increasing serum half-life and extending cholesterol lowering in vivo by engineering an antibody with pH-sensitive binding to PCSK9. J Biol Chem 287:11090-11097.
2. Christianson GJ, Brooks W, Vekasi S, Manolfi EA, Niles J, Roopenian SL, Roths JB, Rothlein R, and Roopenian DC (1997) Beta 2-microglobulin-deficient mice are protected from hypergammaglobulinemia and have defective antibody responses because of increased IgG catabolism. J Immunol 159:4781-4792.
3. Dall'Acqua WF, Kiener PA, and Wu H (2006) Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J Biol Chem 281:23514-23524.
4. Dall'Acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Brewah YA, Wu H, Kiener PA, and Langermann S (2002) Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol 169:5171-5180.
5. Datta-Mannan A, Witcher DR, Lu J, and Wroblewski VJ (2012) Influence of improved FcRn binding on the subcutaneous bioavailability of monoclonal antibodies in cynomolgus monkeys. MAbs 4:267-273.
6. Datta-Mannan A, Witcher DR, Tang Y, Watkins J, Jiang W, and Wroblewski VJ (2007a) Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates. Drug Metab Dispos 35:86-94.
7. Datta-Mannan A, Witcher DR, Tang Y, Watkins J, and Wroblewski VJ (2007b) Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor. J Biol Chem 282:1709-1717.
8. Deng R, Loyet KM, Lien S, Iyer S, DeForge LE, Theil FP, Lowman HB, Fielder PJ, and Prabhu S (2010) Pharmacokinetics of humanized monoclonal anti-tumor necrosis factor-{alpha} antibody and its neonatal Fc receptor variants in mice and cynomolgus monkeys. Drug Metab Dispos 38:600-605.
9. Ghetie V, Hubbard JG, Kim JK, Tsen MF, Lee Y, and Ward ES (1996) Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur J Immunol 26:690-696.
10. Ghetie V and Ward ES (1997) FcRn: the MHC class I-related receptor that is more than an IgG transporter. Immunol Today 18:592-598.
11. Goebl NA, Babbey CM, Datta-Mannan A, Witcher DR, Wroblewski VJ, and Dunn KW (2008) Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells. Mol Biol Cell 19:5490-5505.
12. Gurbaxani B, Dela Cruz LL, Chintalacharuvu K, and Morrison SL (2006) Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life. Mol Immunol 43:1462-1473.
13. Hinton PR, Johlfs MG, Xiong JM, Hanestad K, Ong KC, Bullock C, Keller S, Tang MT, Tso JY, Vásquez M, et al. (2004) Engineered human IgG antibodies with longer serum half-lives in primates. J Biol Chem 279:6213-6216.
14. Hinton PR, Xiong JM, Johlfs MG, Tang MT, Keller S, and Tsurushita N (2006) An engineered human IgG1 antibody with longer serum half-life. J Immunol 176:346-356.
15. Igawa T, Tsunoda H, Tachibana T, Maeda A, Mimoto F, Moriyama C, Nanami M, Sekimori Y, Nabuchi Y, Aso Y, et al. (2010) Reduced elimination of IgG antibodies by engineering the variable region. Protein Eng Des Sel 23:385-392.
16. Khawli LA, Goswami S, Hutchinson R, Kwong ZW, Yang J, Wang X, Yao Z, Sreedhara A, Cano T, Tesar D, et al. (2010) Charge variants in IgG1: isolation, characterization, in vitro binding properties and pharmacokinetics in rats. MAbs 2:613-624.
17. Kunkel TA, Roberts JD, and Zakour RA (1987) Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol 154:367-382.
18. Ober RJ, Martinez C, Lai X, Zhou J, and Ward ES (2004a) Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level. Proc Natl Acad Sci USA 101:11076-11081.
19. Ober RJ, Martinez C, Vaccaro C, Zhou J, and Ward ES (2004b) Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn. J Immunol 172:2021-2029.
20. Prabhat P, Ram S, Ward ES, and Ober RJ (2004) Simultaneous imaging of different focal planes in fluorescence microscopy for the study of cellular dynamics in three dimensions. IEEE Trans Nanobioscience 3:237-242.
21. Stubenrauch K, Wessels U, Regula JT, Kettenberger H, Schleypen J, and Kohnert U (2010) Impact of molecular processing in the hinge region of therapeutic IgG4 antibodies on disposition profiles in cynomolgus monkeys. Drug Metab Dispos 38:84-91.
22. Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, and Yamaguchi T (2010) Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol 184:1968-1976.
23. Wang W, Vlasak J, Li Y, Pristatsky P, Fang Y, Pittman T, Roman J, Wang Y, Prueksaritanont T, and Ionescu R (2011) Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies. Mol Immunol 48:860-866.
24. Ward ES, Martinez C, Vaccaro C, Zhou J, Tang Q, and Ober RJ (2005) From sorting endosomes to exocytosis: association of Rab4 and Rab11 GTPases with the Fc receptor, FcRn, during recycling. Mol Biol Cell 16:2028-2038.
25. Ward ES, Zhou J, Ghetie V, and Ober RJ (2003) Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans. Int Immunol 15:187-195.
26. West AP Jr and Bjorkman PJ (2000) Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor. Biochemistry 39:9698-9708.
27. Yeung YA, Leabman MK, Marvin JS, Qiu J, Adams CW, Lien S, Starovasnik MA, and Lowman HB (2009) Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol 182:7663-7671.
28. Yeung YA, Wu X, Reyes AE 2nd, Vernes JM, Lien S, Lowe J, Maia M, Forrest WF, Meng YG, Damico LA, et al. (2010) A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life. Cancer Res 70:3269-3277.